Praluent (alirocumab)

pCPA File Number: 21075
Negotiation Status:
Concluded without agreement
Indication(s):
Atherosclerotic cardiovascular disease
Sponsor/Manufacturer:
Sanofi-Aventis Canada Inc.
CDA-AMC Project Number:
Not Applicable
pCPA Engagement Letter Issued:
Negotiation Process Concluded: